Trials & Filings

SELLAS Achieves Immune Response Data in Triple Negative Breast Cancer

NPS-Specific Cytotoxic T-Lymphocyte mean frequencies increased by 2.86-fold compared to Baseline at 30 months

SELLAS Life Sciences Group, Inc. announced results from a preplanned analysis of immunologic responses in the cohort of patients with triple negative breast cancer (TNBC) from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial of nelipepimut-S (NPS) +/- trastuzumab (Herceptin®) targeting HER2 low-expressing breast cancer patients.  “Effective adjuvant/maintenance therapy strategies are urgently needed to prevent recurrence or to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters